SCHEMBL4181900

SCHEMBL4181900

O=C(O)c1ccc(-c2ncc(C(F)(F)F)cc2Cl)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.52
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 2/20 0.52
POLB P06746 1/20 0.52
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
MAPT P10636 2/20 0.50
MAPK1 P28482 2/20 0.50
HTT P42858 1/20 0.50
HPGD P15428 2/20 0.48
GLA P06280 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.45
RORC P51449 1/20 0.44
LMNA P02545 1/20 0.44
XBP1 P17861 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PKM P14618 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179360 0.90 SORT1 (0.51) SORT1SMN1; SMN2ALDH1A1KDM4EPOLB
SCHEMBL31239091 0.89 SMN1; SMN2 (0.52) SORT1SMN1; SMN2ALDH1A1KDM4EPOLB
SCHEMBL6174846 0.89 SMN1; SMN2 (0.52) SORT1SMN1; SMN2ALDH1A1KDM4EPOLB
SCHEMBL4182244 0.83 NPC1 (0.56) SMN1; SMN2ALDH1A1KDM4EPOLBNPC1
SCHEMBL4184573 0.81 TSHR (0.56) SMN1; SMN2ALDH1A1HPGDPDK2
SCHEMBL4189721 0.81 ALDH1A1 (0.56) SORT1SMN1; SMN2ALDH1A1KDM4EPOLB
SCHEMBL6177094 0.81 ALDH1A1 (0.52) SORT1SMN1; SMN2ALDH1A1KDM4EPOLB
SCHEMBL6179024 0.80 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1KDM4EPOLBNPC1
SCHEMBL27433850 0.80 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1KDM4EPOLBNPC1
SCHEMBL1818435 0.77 KDM4E (0.62) SORT1SMN1; SMN2ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP disclosed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 SORT1 3854/4885SMN1; SMN2 1331/4885ALDH1A1 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.